What is Fuller Laboratories?
Fuller Laboratories operates at the intersection of clinical diagnostics and veterinary medicine, specializing in the development of high-precision assays for vector-borne and zoonotic diseases. With a legacy spanning over three decades, the firm has established itself as a critical supplier for reference laboratories globally. Their product portfolio, which includes sophisticated IFA, MIF, and ELISA formats, is engineered to meet rigorous standards for sensitivity and repeatability. By providing essential diagnostic tools to both U.S. and international markets, Fuller Laboratories serves as a foundational pillar in the global infectious disease surveillance ecosystem, ensuring that clinical and veterinary practitioners have access to reliable, high-throughput testing solutions.
How much funding has Fuller Laboratories raised?
Fuller Laboratories has raised a total of $514K across 2 funding rounds:
Debt
$150K
Debt
$364K
Debt (2020): $150K with participation from PPP
Debt (2021): $364K led by PPP
Key Investors in Fuller Laboratories
PPP
Public-Private Partnership
What's next for Fuller Laboratories?
With the recent deployment of $364K, Fuller Laboratories is well-positioned to accelerate its research and development pipeline, focusing on the next generation of zoonotic disease detection. The strategic utilization of this capital suggests a focus on expanding manufacturing capacity and enhancing the sensitivity of existing immunoassay platforms. As the global demand for rapid, accurate diagnostic testing continues to rise, the company is expected to leverage its established market presence to capture additional share in the veterinary and clinical diagnostic sectors. Future growth will likely be driven by the integration of advanced automation in assay processing and the expansion of their international distribution network, ensuring that their diagnostic solutions remain at the forefront of the industry.
See full Fuller Laboratories company page
